CA2373879A1 - Therapie antivirale - Google Patents
Therapie antivirale Download PDFInfo
- Publication number
- CA2373879A1 CA2373879A1 CA002373879A CA2373879A CA2373879A1 CA 2373879 A1 CA2373879 A1 CA 2373879A1 CA 002373879 A CA002373879 A CA 002373879A CA 2373879 A CA2373879 A CA 2373879A CA 2373879 A1 CA2373879 A1 CA 2373879A1
- Authority
- CA
- Canada
- Prior art keywords
- hiv
- viral
- treatment
- pharmaceutical composition
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
l'invention relève du domaine des agents antiviraux et plus particulièrement de la thérapie antivirale. L'invention concerne l'utilisation d'au moins un composé ou d'un mélange de composés correspondant à la formule générale (I) ou encore d'un équivalent fonctionnel ou d'un sel ou d'un hydrate pharmaceutiquement acceptable de celui-ci, qui vise la production d'une composition pharmaceutique destinée au traitement d'une infection virale.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14229799P | 1999-07-02 | 1999-07-02 | |
US60/142,297 | 1999-07-02 | ||
EP99202156.8 | 1999-07-02 | ||
EP99202156A EP1064940A1 (fr) | 1999-07-02 | 1999-07-02 | Thérapie antivirale |
EP00200991 | 2000-03-17 | ||
EP00200991.8 | 2000-03-17 | ||
PCT/NL2000/000460 WO2001001985A1 (fr) | 1999-07-02 | 2000-06-30 | Therapie antivirale |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2373879A1 true CA2373879A1 (fr) | 2001-01-11 |
Family
ID=56290036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002373879A Abandoned CA2373879A1 (fr) | 1999-07-02 | 2000-06-30 | Therapie antivirale |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1194141B1 (fr) |
JP (1) | JP2003503455A (fr) |
AT (1) | ATE301997T1 (fr) |
AU (1) | AU5856100A (fr) |
CA (1) | CA2373879A1 (fr) |
DE (1) | DE60022047T2 (fr) |
WO (1) | WO2001001985A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10148886A1 (de) * | 2001-10-04 | 2003-04-30 | Avontec Gmbh | Inhibition von STAT-1 |
EP1452605A1 (fr) * | 2003-02-27 | 2004-09-01 | Universiteit Utrecht Holding B.V. | Procédé de détermination d'activité antivirale |
EP3510172B1 (fr) * | 2016-09-07 | 2023-11-29 | St Vincent's Hospital Sydney Limited | Méthodes de détection du vih |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998028292A1 (fr) * | 1996-12-23 | 1998-07-02 | Smithkline Beecham Corporation | Nouveaux composes renfermant de la piperidine |
US5973191A (en) * | 1996-12-30 | 1999-10-26 | Vanderbilt University | Selective inhibitors of prostaglandin endoperoxide synthase-2 |
CA2313049A1 (fr) * | 1997-12-17 | 1999-06-24 | Cornell Research Foundation, Inc. | . inhibition de la cyclooxygenase-2 |
-
2000
- 2000-06-30 AU AU58561/00A patent/AU5856100A/en not_active Abandoned
- 2000-06-30 WO PCT/NL2000/000460 patent/WO2001001985A1/fr active IP Right Grant
- 2000-06-30 AT AT00944469T patent/ATE301997T1/de not_active IP Right Cessation
- 2000-06-30 EP EP00944469A patent/EP1194141B1/fr not_active Expired - Lifetime
- 2000-06-30 DE DE60022047T patent/DE60022047T2/de not_active Expired - Fee Related
- 2000-06-30 JP JP2001507477A patent/JP2003503455A/ja active Pending
- 2000-06-30 CA CA002373879A patent/CA2373879A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE301997T1 (de) | 2005-09-15 |
DE60022047T2 (de) | 2006-06-29 |
WO2001001985A1 (fr) | 2001-01-11 |
EP1194141A1 (fr) | 2002-04-10 |
DE60022047D1 (de) | 2005-09-22 |
JP2003503455A (ja) | 2003-01-28 |
EP1194141B1 (fr) | 2005-08-17 |
AU5856100A (en) | 2001-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rice et al. | Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins | |
CN104136081B (zh) | 再活化潜伏hiv病毒的巨大戟二萜醇衍生物 | |
US20080038716A1 (en) | Cell lines with latent immunodeficiency virus and methods of use thereof | |
Hartman et al. | The Continuing Evolution of HIV‐1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets | |
WO2008088806A1 (fr) | Paradigme combinatoire combattant les infections vih, vih/hsv ou vih/hpv chez l'être humain au moyen de composés végétaux de faible masse moléculaire | |
KR20020024587A (ko) | 염증 매개성 감염에 대한 항염증 치료 | |
US6787573B2 (en) | Antiviral therapy | |
WO2010099169A2 (fr) | Nouveau modèle in vitro de latence du vih-1 pour le criblage d'agents de réactivation du vih-1 | |
Baba | Cellular factors as alternative targets for inhibition of HIV-1 | |
EP1194141B1 (fr) | Therapie antivirale | |
US20160015759A1 (en) | Compositions and methods for treating an immunodeficiency virus infection | |
US6387959B1 (en) | Antiviral therapy | |
EP1263429B1 (fr) | Therapie antivirale | |
EP1064940A1 (fr) | Thérapie antivirale | |
US20110305662A1 (en) | Methods of treating immunodeficiency virus infection | |
JUNKER et al. | Antiviral Potency of Drug—Gene Therapy Combinations against Human Immunodeficiency Virus Type 1 | |
Mannioui et al. | Cell cycle regulation of human immunodeficiency virus type 1 integration in T cells: antagonistic effects of nuclear envelope breakdown and chromatin condensation | |
Richard | Documentation and molecular analysis of African medicinal plants and naturally-produced chemical compounds that modulate latent HIV-1 infection | |
EP1452605A1 (fr) | Procédé de détermination d'activité antivirale | |
WO1997034593A1 (fr) | AGONISTES UTILES DANS LA COSTIMULATION DE LYMPHOCYTES T INDUITS PAR TcR/CD3 | |
JP2021187761A (ja) | 抗SARS−CoV−2薬 | |
Warachit et al. | Aberrant life cycle of human immunodeficiency virus type 1 CRF15_01B-like clinical isolates from Thailand in human CD4+ T-cell lines | |
Yang | Dehydroepiandrosterone (DHEA) as a potential anti-human immunodeficiency virus type one agent to investigate the pathogenesis of HIV-1 | |
Laird | TARGETING THE HIV-1 LATENT RESERVOIR FOR ERADICATION USING SMALL MOLECULES | |
HealthCare | Reinhold Welker Bayer HealthCare, Wuppertal, Germany Helga Rübsamen-Waigmann Bayer HealthCare, Wuppertal, and University of Frankfurt, Frankfurt, Germany |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |